Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Short

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
The American Journal of Medicine|November 2, 2010
Muehrcke's linesNicholas Short, Chirayu Shah
JAMA Oncology|March 25, 2021
The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-ReplyFarhad Ravandi, Shouhao Zhou, Nicholas Short
Blood and Lymphatic Cancer : Targets and Therapy|March 28, 2022
Clinical Value of Measurable Residual Disease in Acute Lymphoblastic LeukemiaKyaw Hein, Nicholas Short, Elias Jabbour, et al.
Cancer Cell International|April 30, 2005
Dietary omega-3 fatty acids and ionizing irradiation on human breast cancer xenograft growth and angiogenesisW Elaine Hardman, LuZhe Sun, Nicholas Short, et al.
Cancer Cell International|May 28, 2005
Endothelial cell pseudopods and angiogenesis of breast cancer tumorsIvan L Cameron, Nicholas Short, Luzhe Sun, et al.
Cancer Cell International|July 28, 2005
Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasisIvan L Cameron, Lu-Zhe Sun, Nicholas Short, et al.
Leukemia & Lymphoma|July 6, 2025
Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patientsMehmet Sevki Uyanik, Elias Jabbour, Nicholas Short, et al.
Journal of Cancer Research and Clinical Oncology|August 28, 2022
Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effectsCynthia Liu, Rajan Amin, Malek Shatila, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 2, 2024
Outcome of Patients With Relapsed Acute Promyelocytic LeukemiaKoji Sasaki, Farhad Ravandi, Tapan Kadia, et al.
American Journal of Hematology|May 15, 2021
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemiaNitin Jain, Abhishek Maiti, Farhad Ravandi, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
The American Journal of Medicine|November 2, 2010
Muehrcke's linesNicholas Short, Chirayu Shah
JAMA Oncology|March 25, 2021
The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-ReplyFarhad Ravandi, Shouhao Zhou, Nicholas Short
Blood and Lymphatic Cancer : Targets and Therapy|March 28, 2022
Clinical Value of Measurable Residual Disease in Acute Lymphoblastic LeukemiaKyaw Hein, Nicholas Short, Elias Jabbour, et al.
Cancer Cell International|April 30, 2005
Dietary omega-3 fatty acids and ionizing irradiation on human breast cancer xenograft growth and angiogenesisW Elaine Hardman, LuZhe Sun, Nicholas Short, et al.
Cancer Cell International|May 28, 2005
Endothelial cell pseudopods and angiogenesis of breast cancer tumorsIvan L Cameron, Nicholas Short, Luzhe Sun, et al.
Cancer Cell International|July 28, 2005
Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasisIvan L Cameron, Lu-Zhe Sun, Nicholas Short, et al.
Leukemia & Lymphoma|July 6, 2025
Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patientsMehmet Sevki Uyanik, Elias Jabbour, Nicholas Short, et al.
Journal of Cancer Research and Clinical Oncology|August 28, 2022
Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effectsCynthia Liu, Rajan Amin, Malek Shatila, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 2, 2024
Outcome of Patients With Relapsed Acute Promyelocytic LeukemiaKoji Sasaki, Farhad Ravandi, Tapan Kadia, et al.
American Journal of Hematology|May 15, 2021
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemiaNitin Jain, Abhishek Maiti, Farhad Ravandi, et al.
Pageof 5